Hot on the heels of its FDA approval, a new combo pill from the HIV-focused partnership of GlaxoSmithKline and Pfizer, has won approval in Europe. ViiV Healthcare said that the EU had given a green light to its once daily combo pill Triumeq, an approval that will help it reach the $5 billion in peak sales it has been forecast to capture.
AstraZeneca didn't just fan the flames of U.K. politicial opposition to fend off Pfizer's $117 billion takeover attempt earlier this year. The British drugmaker also took its lobbying to Washington.
Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this week.
The story about a potential new takeover offer for AstraZeneca by Pfizer will not die.
Look out, Sanofi. Pfizer's Clostridium difficile candidate has just nabbed an FDA fast-track designation that should help it pick up some ground in the race to bring the first vaccine for the disease to market.
Earlier this year, when Pfizer made a play for rival pharma giant AstraZeneca, CEO Ian Read listed the British drugmaker's vaccines portfolio as a motivating factor. Now, rumors are swirling that the company could be eyeing Actavis as a backup plan. On the one hand, the New Jersey generics maker lacks vaccines offerings. And on the other, with the recent developments affecting Pfizer's unit, how much does that matter?
Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules.
Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.
Merck and Pfizer have struck a deal to add the immuno-oncology superstar pembrolizumab to Xalkori for ALK-positive cases of advanced non-small cell lung cancer.
Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.